
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
San Francisco-Despite a settlement by TAP Pharmaceuticals last fall on charges concerning fraudulent pricing and marketing of leuprolide acetate (Lupron)





